Safety and efficacy of use of demineralised bone matrix in orthopaedic and trauma surgery

Expert Opinion on Drug Safety

Volumn 5, Issue 6, 2006, Pages 847-866

  Dinopoulos, Haralampos T H ^a   Giannoudis, Peter V ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Demineralised bone matrix; Orthopaedic; Osteoinduction; Trauma

Indexed keywords

BONE MORPHOGENETIC PROTEIN; GLYCEROL; GROWTH FACTOR;

AUTOIMMUNE DISEASE; BACKACHE; BIOMECHANICS; BONE CONDUCTION; BONE DEFECT; BONE DEVELOPMENT; BONE GRAFT; BONE MATRIX; BONE STRENGTH; BONE STRUCTURE; CANCER; CENTRAL NERVOUS SYSTEM INFECTION; CHILL; CONSCIOUSNESS DISORDER; CYTOTOXICITY; DENTAL SURGERY; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; ECTOPIC TISSUE; GLAUCOMA; HEALTH CARE FACILITY; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINURIA; HOST; HUMAN; HYPERGLYCEMIA; HYPEROSMOLALITY; INFECTION; INTRAVASCULAR HEMOLYSIS; JAUNDICE; KIDNEY INJURY; MICROENVIRONMENT; NAUSEA; NEUROLYSIS; NEUROSURGERY; NONHUMAN; OLIGURIA; ORTHOPEDIC SURGERY; PATIENT SAFETY; PLASTIC SURGERY; REVIEW; REYE SYNDROME; STRESS; STROKE; THERAPY EFFECT; TRAUMATOLOGY; TREATMENT RESPONSE; UNITED STATES;

ANIMALS; BONE MATRIX; BONE SUBSTITUTES; BONE TRANSPLANTATION; HUMANS; WOUNDS AND INJURIES;

EID: 33750567341     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.6.847     Document Type: Review

References (168)

1. URIST MR: Bone: formation by autoinduction. Science (1965) 150:893-899.
2. URIST MR, SILVERMAN BF, BURING K, DUBUC FL, ROSENBERG JM: The bone induction principle. Clin. Orthop. (1967) 53:243-283.
3. URIST M: The search for and the discovery of bone morphogenetic protein (BMP). In: Bone Grafts, Derivatives and Substitutes. Urist M, O'Connor B, Burwell RG (Eds), Oxford, Butterworth-Heinemann (1994):315-362.
4. HUGGINS CB, URIST MR: Dentin matrix transformation: rapid induction of alkaline phosphatase and cartilage. Science (1970) 167(919):868-898.
5. REDDI AH, HUGGINS CB: Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc. Natl. Acad. Sci. USA (1972) 69:1601-1605.
6. TRUUMEES E, HERKOWITZ HN: Alternatives to autologous bone harvest in spine surgery. Univ. Penn. Orthop. J. (1999) 12:77-88.
7. LUDWIG SC, BODEN SD: Osteoinductive bone graft substitutes for spinal fusion: a basic science summary. Orthop. Clin. North Am. (1999) 30:635-645.
8. SANDHU HS, GREWAL HS, PARVATANENI H: Bone grafting for spinal fusion. Orthop. Clin. North Am. (1999) 30:685-698.
9. FLEMING JEJ, CORNELL CN, MUSCHLER GF: Bone cells and matrices in orthopedic tissue engineering. Orthop. Clin. North Am. (2000) 31:357-374.
10. KHAN SN, TOMIN E, LANE JM: Clinical applications of bone graft substitutes. Orthop. Clin. North Am. (2000) 31:389-398.
11. SASSARD WR, EIDMAN DK, GRAY PMJ et al.: Augmenting local bone with Grafton demineralised bone matrix for posterolateral lumbar spine fusion: avoiding second site autologous bone harvest. Orthopedics (2000) 23:1059-1065.
12. SHIGEYAMA Y, D'ERRICO JA, STONE R, SOMERMAN MJ: Commercially prepared allograft material has biological activity in vitro. J. Peridontal (1995) 66:478-487.
13. WOZNEY JM: The bone morphogenetic protein family and osteogenesis. Mol. Reprod. Dev. (1992) 32:160-167.
14. BAUER, TW, MUSCHLER GF: Bone graft materials: an overview of the basic science. Clin. Orthop. Relat. Res. (2000) 371:10-27.
15. LADD AL, PLIAM NB: Use of bone graft substitutes in distal radius fractures. J. Am. Acad. Orthop. Surg. (1999) 7:279-290.
16. EDWARDS JT, DIEGMANN MH, SCARBOROUGH NL: Osteoinduction of human demineralized bone: Characterization in a rat model. Clin. Orthop. (1998) 357:219-228.
17. MUSCHLER GF, NEGAMI S, HYODO A et al.: Evaluation of collagen ceramic composite graft materials in a spinal fusion model. Clin. Orthop. (1996) 328:250.
18. TEIDEMAN JJ, CONNOLLY JF, STRATES BS et al.: Treatment of nonunion by percutaneous injection of bone marrow and demineralized bone matrix: An experimental study in dogs. Clin. Orthop. (1991) 268:294-302.
19. ALPER G, BERNICK S, YAZDI M et al.: Osteogenesis in bone defects in rats: The effects of hydroxyapatite and demineralized bone matrix. Am. J. Med. Sci. (1989) 298:371-376.
20. REDDI AH: Initiation of fracture repair by bone morphogenetic proteins. Clin. Orthol. (1998) 355(Suppl.):S66-S72.
21. REDDI AH: Bone morphogenetic proteins: from basic science to clinical applications. J. Bone Joint Am. Surg. (2001) 83A(Suppl.):S1-S6.
22. BLUM B, MOSELEY J, MILLER L et al.: Measurement of bone morphogenetic proteins and other growth factors in demineralised bone matrix. Orthopaedics (2004) 27(1 Suppl.):S161-S165.
23. KANIM LEA, BAE H, ZHAO L et al.: Inter- and intravariability of BMPs in commercially available demineralised bone matrices. Proceedings of the North American Spine Society 18th Annual Meeting, October 2003. Spine J. (2003) 3(Suppl.):81S.
24. PIETRZAK WS, PERNS SV, KEYES J, WOODELL-MAY J, MCDONALD NM: Demineralized bone matrix graft: a scientific and clinical case study assessment. J. Foot-Ankle Surg. (2005) 44(5):345-353.
25. MCLEAN VA: AATB information alert. American Association of Tissue Banks (1993).
26. AD HOC WORKING PARTY ON BIOTECHNOLOGY/PHARMACY: Validation of virus removal and inactivation procedures. Pharmacol. Toxicol. (1991) 69:144-148.
27. URIST MR, DAWSON E: Intertransverse process fusion with the aid of chemosterilized autolyzed antigen-extracted allogenic (AAA) bone. Clin. Orthop. (1981) 154:97-113.
28. PIETRZAK WS, MILLER SD, KUCHARZYK DW, LESSEK TP, HAMMAN NM, WOODELL J: Demineralized bone graft formulations: design, development, and a novel example. Proceedings of the Pittsburgh Bone Symposium, Sheraton Station Square Hotel, Pittsburgh, PA, USA, 20 - 23 August (2003):557-576.
29. SCARBOROUGH NL, WHITE EM, HUGHES JV, MANRIQUE AJ, POSER JW: Allograft safety: viral inactivation with bone demineralization. Contemp. Orthop. (1995) 31(4):257-261.
30. ASPENBERG P, JOHNSSON E, THORNGREN KG: Dose-dependent reduction of bone inductive properties by ethylene oxide. J. Bone Joint Surg. Br. (1990) 72:1036-1037.
31. MUNTING E, WILMART JF, WIJNE A, HENNEBERT P, DELLOYE C: Effect of sterilization on osteoinduction. Comparison of five methods in demineralized rat bone. Acta Orthop. Scand. (1988) 59:34-38.
32. GLOWACKI J, MULLIKEN JB: Demineralized bone implants. Clin. Plant Surg. (1985) 12:233-241.
33. HAN B, TANG B, NIMNI ME: Combined effect of phosphatidylcholine and demineralised bone matrix on bone induction. Connect. Tissue Res. (2003) 44:160-166.
34. DAMIEN CJ, PARSONS JR, PREWETT AB, RIETVELD DC, ZIMMERMAN MC: Investigation of an organic delivery system for demineralised bone matrix in a delayed-healing cranial defect model. J. Biomed. Mater. Res. (1994) 28:55341.
35. FRANK MSB, NAHATA MC, HILTY MD: Glycerol: A review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use. Pharmacotherapy (1981) 1:147-160.
36. ROBERGS RA, GRIFFIN SE: Glycerol. Biochemistry, pharmacokinetics and clinical and practical applications. Sports Med. (1998) 26:145-167.
37. HAN B, TANG B, NIMNI M: A quantitative and sensitive in vitro assay of osteoinductive activity of demineralized bone matrix. J. Orthop. Res. (2003) 21(4):648-654.
38. HAYNERT W: Application possibilities of human bone-collagen substance as a transplant in skeletal surgery. Beitr Orthop. Traumatol. (1990) 37:45341.
39. LEIKINA E, MERTTS MV, KUZNETSOVA N, LEIKIN S: Type I collagen is thermally unstable at body temperature. Proc. Natl. Acad. Sci. USA (2002) 99(3):1314-1318.
40. MADDOX E, ZHAN M, MUNDY GR, DROHAN WN, BURGESS WH: Optimizing human demineralized bone matrix for clinical application. Tissue Eng. (2000) 6:441-448.
41. MARDAS N, KOSTOPOULOS L, STAVROPOULOS A, KARRING T: Osteogenesis by guided tissue regeneration and demineralized bone matrix. J. Clin. Periodontol. (2003) 30:17683.
42. REDDI AH, HUGGINS CB: Influence of geometry of transplanted tooth and bone on transformation of fibroblasts. Proc. Soc. Exp. Biol. Med. (1973) 143:6347.
43. ROUGRAFF BT, KLING TJ: Treatment of active unicameral bone cysts with percutaneous injection of demineralized bone matrix and autogenous bone marrow. J. Bone Joint Surg. Am (2002) 84A:921-929.
44. RUSSELL JL, BLOCK JE: Clinical utility of demineralized bone matrix for osseous defects, arthrodesis, and reconstruction: impact of processing techniques and study methodology. Orthopedics (1999) 22:524-531.
45. EDWARDS JT, CHESMEL KD, SCARBOROUGH NL: Osteoinductive performance of various forms of human demineralized bone matrix. Proceedings of the 12th Annual Meeting of the North American Spine Society, New York, USA (1997).
46. MARTIN GJ, BODEN SD, TITUS L et al.: New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis. Spine (1999) 24:637-645.
47. MORONE MA, BODEN BA: Experimental posterolateral lumbar spinal fusion with a demineralized bone matrix gel. Spine (1998) 23:159-167.
48. PREWETT AB, MOYER MP, O'LEARY RK, MELLONIG JT: Decalcification inactivates HIV in spiked and infected bone. Trans. Orthop. Res. Soc. (1992) 17:436.
49. LI RH, WOZNEY JM: Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol. (2001) 19(7):255-265.
50. PARAMORE CG, LAURYSSEN C, RAUZZINO MJ et al.: The safety of OP-1 for lumbar fusion with decompression-a canine study. Neurosurgery (1999) 44(5):1151-(1155) discussion 1155-1156.
51. DAMIEN CJ, GROB D, BODEN SD, BENEDICT JJ: Purified bovine BMP extract and collagen for spine arthrodesis: preclinical safety and efficacy. Spine (2002) 27(16 Suppl. 1):S50-S58.
52. HELM GA, ALDEN TD, BERES EJ et al.: Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J. Neurosurg. (2000) 92(2 Suppl.):191-196.
53. VACCARO AR, PATEL T, FISCHGRUND J et al.: A pilot safety and efficacy study of OP-1 putty (rhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur. Spine J. (2003) 12(5):495-500.
54. MANISCALCO P, GAMBERA D, BERTONE C et al.: Healing of fresh tibial fractures with OP-1. A preliminary report. Acta Biomed. Ateneo Parmense (2002) 73(1-2):27-33.
55. BASKIN DS, RYAN P, SONNTAG V, WESTMARK R, WIDMAYER MA: A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine (2003) 28(12):1219-1225.
56. POYNTON AR, LANE JM: Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine (2002) 27(16 Suppl. 1):S40-S48.
57. SHEEHAN JP, SHEEHAN JM, SEEHERMAN H, QUIGG M, HELM GA: The safety and utility of recombinant human bone morphogenetic protein-2 for cranial procedures in a nonhuman primate model. J. Neurosurg. (2003) 98(1):125-130.
58. MARTIN GJ Jr, BODEN SD, MARONE MA, MOSKOVITZ PA: Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J. Spinal Disord. (1999) 12(3):179-186.
59. MEYER RA Jr, GRUBER HE, HOWARD BA et al.: Safety of recombinant human bone morphogenetic protein-2 after spinal laminectomy in the dog. Spine (1999) 24(8):747-754.
60. BOROVECKI F, JELIC M, GRGUREVIC L et al.: Bone morphogenetic protein-7 from serum of pregnant mice is available to the fetus through placental transfer during early stages of development. Nephron Exp. Nephrol. (2004) 97(1):e26-e32.
61. MASUDA H, FUKABORI Y, NAKANO K, SHIMIZU N, YAMANAKA H: Expression of bone morphogenetic protein-7 (BMP-7) in human prostate. Prostate (2004) 59(1):101-106.
62. NAKANO M, ARAI E, NAKAJIMA Y et al.: Immunohistochemical study of chondrolipoma: possible importance of transforming growth factor (TGF)-betas, latent TGF-beta binding protein-1 (LTBP-1), and bone morphogenetic protein (BMP) for chondrogenesis in lipoma. J. Dermatol. (2003) 30(3):189-195.
63. SEKIYA T, ADACHI S, KOHU K et al.: Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells. J. Biol. Chem. (2004) 279(8):6840-6846.
64. JIN Y, TIPOE CL, LIONG EC et al.: Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. Oral Oncol. (2001) 37(3):225-233.
65. CLEMENT JH, MARR N, MEISSNER A et al.: Bone morphogenetic protein 2 (BMP-2) induces sequential changes of Id gene expression in the breast cancer cell line MCF-7. J. Cancer Res. Clin. Oncol. (2000) 126(5):271-279.
66. KATOH M, TERADA M: Over-expression of bone morphogenic protein (BMP)-4 mRNA in gastric cancer cell lines of poorly differentiated type. J. Gastroenterol. (1996) 31(1):137-139.
67. KAWAMURA C, KIZAKI M, IKEDA Y: Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells. Leuk. Lymphoma (2002) 43(3):635-639.
68. LANGENFELD EM, CALVANO SE, ABOU-NUKTA F et al.: The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis (2003) 24(9):1445-1454.
69. MASUDA H, FUKABORI Y, NAKANO K et al.: Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate (2003) 54(4):268-274.
70. YOSHIKAWA H, TAKAOKA K, MASUHARA K, ONO K, SAKAMOTO Y: Prognostic significance of bone morphogenetic activity in osteosarcoma tissue. Cancer (1988) 61(3):569-573.
71. FRANZEN A, HELDIN NE: BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1)and p27(KIP1). Biochem. Biophys. Res. Commun. (2001) 285(3):773-781.
72. HALLAHAN AR, PRITCHARD JI, CHANDRARATNA RA et al.: BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat. Med. (2003) 9(8):1033-1038.
73. WACH S, SCHIRMACHER P, PROTSCHKA M, BLESSING M: Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members. Oncogene (2001) 20(53):7761-7769.
74. SIMON M, MARESH JG, HARRIS SE et al.: Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am. J. Physiol. (1999) 276(3 Pt 2):F382-F389.
75. KLAHR S: The bone morphogenetic proteins (BMPs). Their role in renal fibrosis and renal function. J. Nephrol. (2003) 16(2):179-185.
76. ZEISBERG M, BOTTIGLIO C, KUMAR N et al.: Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Physiol. Renal Physiol. (2003) 285(6):F1060-F1067.
77. WILLETTE RN, GU JL, LYSKO PG et al.: BMP-2 gene expression and effects on human vascular smooth muscle cells. J. Vasc. Res. (1999) 36(2):120-125.
78. SCHLUESENER HJ, MEYERMANN R: Immunolocalization of BMP-6, a novel TGF-beta-related cytokine, in normal and atherosclerotic smooth muscle cells. Atherosclerosis (1995) 113(2):153-156.
79. DAVIES MR, LUND RJ, HRUSKA KA: BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J. Am. Soc. Nephrol. (2003) 14(6):1559-1567.
80. DORAI H, SAMPATH TK: Bone morphogenetic protein-7 modulates genes that maintain the vascular smooth muscle cell phenotype in culture. J. Bone Joint Surg. Am. (2001) 83A(Suppl. 1) (Pt 1):S70-S78.
81. DAVID SM, GRUBER HE, MEYER RA Jr et al.: Lumbar spinal fusion using recombinant human bone morphogenetic protein in the canine. A comparison of three dosages and two carriers. Spine (1999) 24(19):1973-1979.
82. BODEN SD, MARTIN GJ Jr, MORONE MA, UGBO JL, MOSKOVITZ PA: Posterolateral lumbar intenransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine (1999) 24(12):1179-1185.
83. BODEN SD, KANG J, SANDHU H, HELLER JG: Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (2002) 27(23):2662-2673.
84. INGHAM E, FISHER J: Biological reactions to wear debris in total joint replacement. Proc. Inst. Mech. Eng. [H] (2000) 214(1):21-37.
85. FRIEDLAENDER GE, PERRY CR, COLE JD et al.: Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J. Bone Joint Surg. Am. (2001) 83A(Suppl. 1) (Pt 2):S151-S158.
86. BODEN SD, ZDEBLICK TA, SANDHU HS, HEIM SE: The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine (2000) 25(3):376-381.
87. GOVENDER S, CSIMMA C, GENANT HK et al.: Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J. Bone Joint Surg. Am. (2002) 84A(12):2123-2134.
88. BOSTROM MP, YANG X, KENNAN M, SANDHU H, DICARLO E, LANE JM: An unexpected outcome during testing of commercially available demineralized bone graft materials: how safe are the nonallograft components? Spine (2001) 26(13):1425-1428.
89. WEIBERG REPORT: Review of the clinical safety experience with Grafton demineralized bone matrix. Prepared for Osteotech from the WEIBERG group, Inc. August 10, 2000, Data on file.
90. WITTBJER J, PALMER B, ROHLIN M, THORNGREN KG: Osteogenic activity in composite grafts of demineralized compact bone and marrow. Clin. Orthop. (1983) 173:229-238.
91. ADKISSON HD, STRAUSS-SCHOENBERGER MG, GILLIS M, WILKINS R, JACKSON M, HRUSKA KA: Rapid quantitative bioassay of osteoinduction. J. Orthop. Res. (2000) 18(3):503-511.
92. LINDHOLM TS, URIST MR: A quantitative analysis of new bone formation by induction in compositive grafts of bone marrow and bone matrix. Clin. Orthop. (1980) 150:288-300.
93. WILKINS RM: Clinical effectiveness of demineralized bone matrix assayed in human cell culture. Adv. Tissue Banking (1999) 3:113-124.
94. ASPENBERG P, ANDOLF E: Bone induction by fetal and adult human bone matrix in athymic rats. Acta Orthop. Scand. (1989) 60:195-199.
95. ASPENBERG P, THORNGREN KG, LOHMANDER LS: Rabbit bone matrix induces bone formation in the athymic rat. Acta Orthop. Scand. (1988) 59:276-278.
96. FEIGHAN JE, DAVEY DT, PREWETT AB, STEVENSON S: Induction of bone by a demineralized bone matrix gel: A study in a rat femoral defect model. J. Orthop. Res. (1985) 13:881-891.
97. GEPSTEIN R, WEISS RE, HALLEL T: Bridging large defects in bone by demineralized bone matrix in the form of a powder: A radiographic, histological, and radioisotope-uptake study in rats. J. Bone Joint Surg. Am. (1987) 69A:984-992.
98. OIKARINEN J, KORHONEN LK: Repair of bone defects by bone inductive material. Acta Orthop. Scand. (1979) 60:334-339.
99. HAN B, TANG B, NIMNI ME: Quantitative and sensitive in vitro assay for osteoinductive activity of demineralized bone matrix. J. Ortho. Res. (2003) 21:648-654.
100. LOHMANN CH, ANDREACCHIO D, KOSTER G et al.: Tissue response and osteoinduction of human bone grafts in vivo. Arch. Orthop. Trauma Surg. (2001) 121:583-590.
101. ZHANG M, POWERS RM JR, WOLFINBARGER L Jr: Effect(s) of the demineralization process on the osteoinductivity of demineralized bone matrix. J. Periodontol. (1997) 68:1085-1092.
102. ZHANG M, POWERS RM JR, WOLFINBARGER L Jr: A quantitative assessment of osteoinductivity of human demineralized bone matrix. J. Periodontol. (1997) 68:1076-1084.
103. TRAIANEDES K, RUSSEL JL, EDWARDS JT, STUBBS HA, SHANAHAN IR, KNAACK D: Donor age and gender effects on osteoinductivity of demineralised bone matrix. J. Biomed. Mater. Res. (2004) 70B:21-29.
104. SCHWARTZ Z, SOMERS A, MELLONIG JT et al.: Ability of commercial demineralized freeze-dried bone allograft to induce new bone formation is dependent on donor age but not gender. J. Periodontol. (1998) 69:470-478.
105. URIST MR, STRATES BS: Bone morphogenetic protein. J. Dent. Res. (1971) 50:1392-1406.
106. WLODARSKI KH, REDDI AH: Alkaline phosphatase as a marker of osteoinductive cells. Calcif. Tissue Int. (1986) 39:382-385.
107. BLUM B, MOSELEY J, MILLER L, RICHEKSOPH K, HAGGARD W: Measurement of bone morphogenetic proteins and other growth factors in demineralised bone matrix. Orthopedics (2004) 27(Suppl.):S161-S165.
108. JERGESEN HE, CHUA J, KAO RT, KABAN LB: Age effects on bone induction by demineralised bone powder. Clin. Orthop. (1991) 268:253-259.
109. WOLFINBARGER L JR, ZHENG Y: An in vivo bioassay to assess biological activity in demineralised bone. In Vitro Cell Dev. Biol. (1993) 29A:914-916.
110. KAWAI T, URIST MR: Quantitative computation of induced heterotopic bone formation by an image analysis system. Clin. Orthop. (1988) 233:262-267.
111. CARNES DL, DE LA FONTAINE J, COHRAN DL et al.: Evaluation of 2 novel approaches for assessing the ability for demineralised freeze-dried bone allograft to induce new bone formation. J. Periodontol. (1999) 70:353-363.
112. RUSSELL JL, BLOCK JE: Clinical utility of demineralized bone matrix for osseous defects, arthrodesis, and reconstruction: impact of processing techniques and study methodology. Orthopedics (1999) 22:524-553.
113. HAN B, YANG Z, NIMNI M: Effects of moisture and temperature on the osteoinductivity of demineralized bone matrix. J. Orthop. Res. (2005) 23:855-861.
114. BECKER W, URIST MR, TUCKER IM, BECKER BE: Human demineralised freeze-dried bone: inadequate induced bone formation in athymic rats. A preliminary report. J. Periodontol. (1995) 66:822-828.
115. WERBITT MJ, GOLDBERG PV: The immediate implant: bone preservation and bone regeneration. Int. J. Periodont. Restor. Dent. (1992) 12:206-217.
116. PETERSON B, WHANG P, IGLESIAS R, WANG JC, LIEBERMANN JR: Osteoinductivity of commercially available demineralized bone matrix. Preparations in a spine fusion model. J. Bone Joint Surg. Am. (2004) 86:2243-2250.
117. DI CESARE PE, NIMNI ME, YAZDI M, CHEUNG DT: Effects of lathyritic drugs and lathyritic demineralized bone matrix on induced and sustained osteogenesis. J. Orthop. Res. (1994) 12(3):395-402.
118. YOO J, BIRKEDAL J, CHANG S et al.: Spinal arthrodesis using a demineralized bone/hyaluronan matrix and bone marrow. Proceedings of the NASS 18th Annual Meeting. Spine J. (2003) 3:143S.
119. EDWARDS JL: In vivo osteoinductivity of two human DBM materials: comparative histopathologic evaluation at 14 and 28 days. Iso Tis OrthoBiologics (2003):AW-0166.0.
120. ATTI E, ABJORNSON C, DIEGMANN M et al.: High resolution X-ray computed tomography as a technique to study osteoinductivity of demineralised bone matrix. Proceedings of the NASS 18th Annual Meeting. Spine J. (2003) 3:120S.
121. HAYNERT W: Application possibilities of human bone-collagen substance as a transplant in skeletal surgery. Beitr. Orthop. Traumatol. (1990) 37:45341.
122. MADDOX E, ZHAN M, MUNDY GR, DROHAN WN, BURGESS WH: Optimizing human demineralized bone matrix for clinical application. Tissue Eng. (2000) 6:441-448.
123. SCHWARTZ Z, MELLONIG JT, CARNES DL Jr et al.: Ability of commercial demineralised freeze-dried bone allograft to induce new bone formation. J. Periodontol. (1996) 67:918-926.
124. SAMPATH TK, REDDI AH: Distribution of bone inductive proteins in mineralized and demineralized extracellular matrix. Biochem. Biophys. Res. Commun. (1984) 119:949-954.
125. GLOWACKI J, ALTOBELLI D, MULLIKEN JB: Fate of mineralized and demineralized osseous implants in cranial defects. Calcif. Tissue Int. (1981) 30:71-75.
126. GLOWACKI J, KABLAN LB, MURRAY JE et al.: Application of the biological principle of induced osteogenesis for craniofacial defects. Lancet (1981) 1:959-963.
127. GLOWACKI J, MULLIKEN JB: Demineralised bone implants. Clin. Plast. Surg. (1985) 12:233-236.
128. MULLIKEN JB, GLOWACKI JB: Induced osteogenesis for the repair and reconstruction of the craniofacial region. Plant. Reconstr. Surg. (1980) 65:553-558.
129. TIEDEMAN JJ, GARVIN KL, KILE TA et al.: The role of composite, demineralised bone marrow in the treatment of osseous defects. Orthopedics (1995) 18:1153-1158.
130. MICHELSON JD, CURL LA: Use of demineralised bone matrix in hindfoot arthrodesis. Clin. Orthop. (1996) 325:203-208.
131. WIETROUB S, AND REDDI AH: Influence of irradiation on the osteoinductive potential of demineralized bone matrix. Calcif. Tissue Int. (1988) 42(4):255-260.
132. JERGESEN HE, CHUA J, KAO RT, KABAN LB: Age effects on bone induction by demineralised bone powder. Clin. Orthop. (1991) 268:253-259.
133. GREENWALD S, BODEN SD, GOLDBERG VM et al. FOR THE COMMITTEE ON BIOLOGICAL IMPLANTS: Bone-graft substitutes: facts, fictions and applications. J. Bone Joint Surg. Am. (2001) 83A(Suppl. 2):98-103.
134. CONNOLLY JF: Injectable bone marrow preparations to stimulate osteogenic repair. Clin. Orthop. (1995) 313:8-18.
135. MUSCHLER GF, BOEHM C, EASLEY K: Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J. Bone Joint Surg. Am. (1997) 79:1699-1709. Erratum (1998) 80:302.
136. JACKSON IT, SCHEKER LR, VANDERVORD JG, MCLENNAN JG: Bone marrrow grafting in the secondary closure of alveolar-palatal defects in children. Br. J. Plast. Surg. (1981) 34:422-425.
137. GREER E, HINTON C, TRIFFITT JT: The effect of decalcified bone matrix on the osteogenic potential of bone marrow. Clin. Orthop. (1986) 205:292-298.
138. CONNOLLY JF, GUSE R, TIEDEMAN J, DEHNE R: Autologous marrow injection as a substitute for operative grafting of tibial nonunions. Clin. Orthop. (1991) 266:259-270.
139. UPTON J, GLOWACKI J: Hand reconstruction with allograft demineralised bone: twenty-six implants in twelve patients. J. Hand Surg. [Am] (1992) 17:704-713.
140. WHITEMAN D, GROPPER PT, WIRTZ P, MONK P: Demineralised bone powder. Clinical applications for bone defects of the hand. J. Hand Surg. [Br] (1993) 18:487-490.
141. HU X, YAO L, LU C, WANG S, CHEN Y: Experimental and clinical investigations of human insoluble bone matrix gelatin. A report of 24 cases. Clin. Orthop. (1993) 293:360-365.
142. KAKIUCHI M, HOSOYA T, TAKAOKA K, AMITANI K, ONO K: Human bone matrix gelatin as a clinical alloimplant. A retrospective review of 160 cases. Int. Orthop. (1985) 9:181-188.
143. SWENSON CL, STEVEN P: ARNOCZKY SP: Demineralization for inactivation of infectious retrovirus in systemically infected cortical bone. In-vitro and in-vivo experimental studies. J. Bone Joint Surg. Am. (2003) 85A:323-332.
144. IJIRI S, YAMAMURO T, NAKAMURA T, KOTANI S, NOTOYA K: Effect of sterilization on bone morphogenetic protein. J. Orthop. Res. (1994) 12:628-636.
145. AKKUS O, RIMNAC CM: Fracture resistance of gamma radiation sterilized cortical bone allografts. J. Orthop. Res. (2001) 19:927-934.
146. CONWAY B, TOMFORD WW: Radiosensitivity of human immunodeficiency virus Type 1. Clin. Infect. Dis. (1992) 14:978-979.
147. CORNELL CN, LANE JM, NOTTEBAERT M, KLEIN C: The effect of ethylene oxide sterilization upon the bone induction properties of demineralized bone. Trans. Orthop. Res. Soc. (1987) 12:359.
148. DOHERTY MJ, MOLLAN RA, WILSON DJ: Effects of ethylene oxide sterilization on human demineralized bone. Biomaterials (1993) 14:994-998.
149. FERREIRA SD, DERNELL WS, POWERS BE et al.: Effect of gas-plasma sterilization on the osteoinductive capacity of demineralized bone matrix. Clin. Orthop. (2001) 388:233-239.
150. FIDELER BM, VANGSNESS CT JR, MOORE T, LI Z, RASHEED S: Effect of gamma irradiation on the human immunodeficiency virus. A study in frozen human bone-patellar ligament-bone grafts obtained from infected cadavers. J. Bone Joint Surg. Am. (1994) 76:1032-1035.
151. MELLONIG JT, PREWETT AB, MOYER MP: HIV inactivation in a bone allograft. J. Periodontol. (1992) 63:979-983.
152. SMITH RA, INGELS J, LOCHEMES JJ, DUTKOWSKY JP, PIFER LL: Gamma irradiation of HIV-1. J. Orthop. Res. (2001) 19:815-819.
153. VAN BUEREN J, LARKIN DP, SIMPSON RA: Inactivation of human immunodeficiency virus Type 1 by alcohols. J. Hosp. Infect. (1994) 28:137-148.
154. ASSELMEIER MA, CASPARI RB, BOTTENFIELD S: A review of allograft processing and sterilization techniques and their role in transmission of the human immunodeficiency virus. Am. J. Sports Med. (1993) 21:170-175.
155. JOHN F, KAY JK, VAUGHAN LM: Proportional osteoinduction of DBM graft materials. IsoTis OrthoBiologics, Inc. Data on file.
156. BOSTROM MPG, SEIGERMAN DA: The Clinical use of allografts, demineralized bone matrices, synthetic bone graft substitutes and osteoinductive growth factors: a survey study. Hosp. Spec. Surg. J. (2005) 1:9Y18.
157. ATTIAS N, LINDSEY RW: Management of large segmental tibial defects using a cylindrical mesh cage. Clin. Orthop. Relat. Res. (2006) 450:259-266.
158. ETIENNE G, RAGLAND PS, MONT MA: Use of cancellous bone chips and demineralized bone matrix in the treatment of acetabular osteolysis: preliminary 2-year follow-up. Orthopedics (2004) 27(Suppl.):S123-S126.
159. THALGOTT JS, GIUFFRE JM, FRITTS K, TIMLIN M, KLEZL Z: Instrumented posterolateral lumbar fusion using coralline hydroxyapatite with or without DBM, as an adjunct to autologous bone. Spine J. (2001) 1(2):131-137.
160. THORDARSON DB, KUEHN S: Use of demineralized bone matrix in ankle/ hindfoot fusion. Foot Ankle Int. (2003) 24(7):557-560.
161. WILKINS RM, KELLY CM: The effect of allomatrix injectable putty on the outcome of long bone applications. Orthopedics (2003) 26(5 Suppl.):S567-S570.
162. WILKINS RM, CHIMENTI BT, RIFKIN RM: Percutaneous treatment of long bone nonunions: the use of autologous bone marrow and allograft bone matrix. Orthopedics (2003) 26(5 Suppl.):S549-S554.
163. GIRARDI FP, CAMMISA FP Jr: The effect of bone graft extenders to enhance the performance of iliac crest bone grafts in instrumented lumbar spine fusion. Orthopedics (2003) 26(5 Suppl.):S545-S548.
164. PRICE CT, CONNOLLY JF, CARANTZAS AC, ILYAS I: Comparison of bone grafts for posterior spinal fusion in adolescent idiopathic scoliosis. Spine (2003) 28(8):793-798.
165. ZIRAN B, CHEUNG S, SMITH W, WESTERHEIDE K: Comparative efficacy of 2 different demineralized bone matrix allografts in treating long-bone nonunions in heavy tobacco smokers. Am. J. Orthop. (2005) 34(7):329-332.
166. KANELLOPOULOS AD, YIANNAKOPOULOS CK, SOUCACOS PN: Percutaneous reaming of simple bone cysts in children followed by injection of demineralized bone matrix and autologous bone marrow. J. Pediatr. Orthop. (2005) 25(5):671-675.
167. CAMMISA FP, LOWERY G, GARFIN SR et al.: Two-year fusion rate equivalency between grafton DBM gel and autograft in posterolateral spine fusion: a prospective controlled trial employing a side-by-side comparison in the same patient. Spine (2004) 29(6):660-666.
168. CHEUNG S, WESTERHEIDE K, ZIRAN B: Efficacy of contained metaphyseal and periarticular defects treated with two different demineralized bone matrix allografts. Int. Orthop. (2003) 27:56-59.